BACKGROUND: Gastroesophageal reflux disease (GERD) is the most prevalent acid‐
related disorder in Canada and is associated with significant impairment of health‐related …

An evidence-based appraisal of reflux disease management — the Genval Workshop
Report | Gut Skip to main content Viewing from: Google Indexer BMJ Journals Subscribe …

Functional gut disorders include several clinical entities defined on the basis of symptom
patterns (eg, functional dyspepsia, irritable bowel syndrome, functional abdominal pain …

Background: Esomeprazole, the S‐isomer of omeprazole, is the first proton pump inhibitor to
be developed as an optical isomer. In patients with erosive oesophagitis, esomeprazole has …

Objective: To assess intermittent treatment over 12 months in patients with symptomatic
gastro-oesophageal reflux disease. Design: Randomised, multicentre, double blind …

Onset of action of antisecretory agents is of pivotal importance for patients with
gastroesophageal reflux disease (GERD) treated “on-demand.” Aim To study the acute effect …

GERD prevalence continues to rise in contrast to peptic ulcer disease. The spectrum
contains reflux esophagitis and so‐calledendoscopy‐negative GERD'ornon‐erosive …

Objectives To compare the efficacy and tolerability of pantoprazole 20 mg once daily with
that of esomeprazole 20 mg once daily for 6 months as maintenance therapy in patients with …

Gastro‐oesophageal reflux disease (GERD) is primarily due to incompetence of the lower
oesophageal sphincter (LOS) and crural diaphragm, with transient LOS relaxation frequently …

Background: Successful treatment of gastro-oesophageal reflux disease (GORD) has
traditionally been assessed as healing of reflux oesophagitis, which may not be relevant in …